Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
Author:
Funder
Japan Society for the Promotion of Science
Publisher
Elsevier BV
Subject
General Medicine,Otorhinolaryngology,Surgery
Reference19 articles.
1. Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?;Masuda;Am J Cancer Res,2016
2. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008
3. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
4. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review;Guidi;Med Oncol,2018
5. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer;Schvartsman;Lung Cancer,2017
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma;International Journal of Clinical Oncology;2024-03-30
2. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma;2023-11-28
3. Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck;Frontiers in Oncology;2023-11-21
4. Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy;Cancer Immunology Research;2023-09-05
5. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors;Discover Oncology;2023-08-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3